外周血Galectin-9水平预测异基因造血干细胞移植后急性GVHD
该研究检测29例白血病患者allo-HSCT前后及15例健康志愿者的外周血Galectin-9水平,发现移植前低水平及植活时高水平与aGVHD发生和严重程度相关,植活时高Galectin-9组3年总生存率更低、非复发死亡率更高。
要点
- 移植前低Galectin-9与aGVHD发生相关,植活时高Galectin-9与aGVHD及严重程度相关。
- 植活时Galectin-9≥13.61 μg/L组3年总生存率更低、非复发死亡率更高。
- 植活时Galectin-9可能作为aGVHD发生与严重程度的预测指标。
核心结论
- 移植前及移植后造血干细胞植活时外周血Galectin-9水平有助于评估急性GVHD的发生风险。
研究设计与样本
- 研究纳入29例白血病患者allo-HSCT前、后及15例健康志愿者的外周血标本,用ELISA检测Galectin-9水平。
主要发现
- 急性GVHD组(13例)移植前Galectin-9水平低于未发生急性GVHD组(16例)[(7.96±1.18)μg/L对(12.37±0.97)μg/L,P<0.001]。
- 急性GVHD组植活时Galectin-9水平高于未发生急性GVHD组[(17.78±1.78)μg/L对(9.45±0.80)μg/L,P<0.001]。
- Ⅲ/Ⅳ度急性GVHD组(4例)Galectin-9水平[(23.25±2.59)μg/L]高于Ⅰ/Ⅱ度急性GVHD组(9例)[(14.37±1.45)μg/L]和未发生急性GVHD组(16例)[(9.45±0.80)μg/L](P=0.008,P<0.001)。
- 移植后Galectin-9高表达组(≥13.61 μg/L,13例)3年总生存率低于低表达组(<13.61 μg/L,16例)[(69.23±12.80)%对(100.00±6.05)%,P=0.009]。
- 高表达组非复发死亡率高于低表达组[(23.08±11.69)%对(0.00±7.39)%,P=0.023],3年累积复发率差异无统计学意义[(8.33±7.98)%对(12.50±8.27)%,P=0.708]。
关键数值与推荐
- 移植后Galectin-9高表达组界定为≥13.61 μg/L,低表达组为<13.61 μg/L。
临床怎么用
- 可考虑在allo-HSCT植活时检测外周血Galectin-9水平,辅助评估aGVHD发生风险及严重程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate possible effects of Gelctin-9 on acute graft versus host disease (aGVHD) development and clinical outcomes in patients before and afer allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Methods: Peripheral blood samples were obtained from 29 patients and 15 healthy volunteers with heparin anticoagulant tubes. Samples were analyzed using ELISA kits to measure the serum concentrations of Galectin-9. Results: Patients developing aGVHD had significantly lower level of Galectin-9 [ (7.96±1.18) μg/L] before allo-HSCT compared with those not developing aGVHD [ (12.37±0.97) μg/L, P<0.001]. And after allo-HSCT, the consentration of Galectin-9 increased markedly in patients developing aGVHD [ (17.78±1.78) μg/L] compared with those not developing aGVHD [ (9.45±0.80) μg/L, P<0.001]. Patients developing 3-4 grade aGVHD had significantly higher level of Galectin-9 [ (23.25±2.59) μg/L] compared with those developing 1-2 grade aGVHD [ (14.37±1.45) μg/L, P=0.008] and those without aGVHD [ (9.45±0.80) μg/L, P<0.001]. The patients with lower level of Galectin-9 after allo-HSCT (<13.61 μg/L) showed more favorable clinical outcomes compared with those with higher level of Galectin-9 (≥13.61 μg/L) . The 3-year overall survival rates were (100.00±6.05) % and (69.23±12.80) %, respectively (P=0.009) . The cumulative incidence of non-relapse mortality was significantly higher in high Galectin-9 group [ (23.08±11.69) %] in comparison with low Gaelctin-9 group [ (0.00±7.39) %] (P=0.023) . There was no significant difference between the two groups in terms of the cumulative incidence of relapse. The cumulative incidence of relapse at 3 years were (8.33±7.98) % and (12.50±8.27) % in high and low Galectin-9 groups, respectively (P=0.708) . Conclusions: The serum concentration of Galectin-9 at the time of engraftment after allo-HSCT may be used as a predictor for the development and severity of aGVHD. Galectin-9 might be considered as a potential new approach to regulate transplant rejection to achieve desirable survival. 目的: 探讨外周血半乳糖凝集素9(Galectin-9)水平对异基因造血干细胞移植(allo-HSCT)后急性GVHD的预测作用。 方法: 采集29例白血病患者allo-HSCT前、后及15例健康志愿者的外周血标本(肝素抗凝),用酶联免疫吸附测定法检测Galectin-9水平。 结果: 急性GVHD组(13例)移植前Galectin-9水平低于未发生急性GVHD组(16例)[(7.96±1.18)μg/L对(12.37±0.97)μg/L,P<0.001]。急性GVHD组植活时Galectin-9水平高于未发生急性GVHD组[(17.78±1.78)μg/L对(9.45±0.80)μg/L,P<0.001],Ⅲ/Ⅳ度急性GVHD组(4例)Galectin-9水平[(23.25±2.59)μg/L]高于Ⅰ/Ⅱ度急性GVHD组(9例)[(14.37±1.45)μg/L]和未发生急性GVHD组(16例)[(9.45±0.80)μg/L](P=0.008,P<0.001)。移植后Galectin-9高表达组(≥13.61 μg/L,13例)3年总生存率低于Galectin-9低表达组(<13.61 μg/L,16例)[(69.23±12.80)%对(100.00±6.05)%,P=0.009],非复发死亡率高于低表达组[(23.08±11.69)%对(0.00±7.39)%,P=0.023],3年累积复发率差异无统计学意义[(8.33±7.98)%对(12.50±8.27)%,P=0.708]。 结论: 移植前及移植后造血干细胞植活时外周血Galectin-9水平有助于评估急性GVHD的发生风险。.
引用
- Yin J, Cao Y, Zhou JF, et al. [Prediction of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation by the level of galectin-9 in peripheral blood]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32023750. doi:10.3760/cma.j.issn.0253-2727.2020.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。